The 4th Annual Bringing Chemistry to Medicine Symposium will feature talks by leading experts from around the globe working at the interface of chemical and biomedical sciences. Speakers represent expertise across various research areas, including therapeutic regulation of transcription and chromatin, computational biology, and chemical biology. The event will be hosted in a hybrid format with options to attend in-person or virtually. This two day event will focus on two themes:
- Thursday, October 5: Transcription Therapy
- Friday, October 6: Frontiers in Chemical Biology
Bringing Chemistry to Medicine is hosted by the St. Jude Department of Chemical Biology and Therapeutics and the St. Jude Comprehensive Cancer Center, and is a component of the institution’s strategic objective to establish a global hub focused on the emerging field of transcription-targeted therapeutics.
Attendees are encouraged to attend in person to enjoy enhanced networking and collaboration and experience the beautiful St. Jude campus in Memphis, TN.
To enable broad participation and interaction among trainees and scientists world-wide, registration costs for in-person attendees have been kept to a minimum ($100). Attendance is free for all in-person attendees who present posters and all virtual attendees. A limited number of travel awards will be available (please see abstract submission details below).
A full speaker list and two-day program will be announced soon. This year’s exciting lineup already includes:
- Karen Adelman, PhD
- Paramjit Arora, PhD
New York University
- Cheryl Arrowsmith, PhD
University of Toronto
- David Baker, PhD
University of Washington
- Shelley Berger, PhD
University of Pennsylvania
- Jay Bradner, MD
- Sara Buhrlage, PhD
Dana-Farber Cancer Institute
Harvard Medical School
- Gerald Crabtree, MD
- Emily Dykhuizen, PhD
- Chuan He, PhD
University of Chicago
- Nada Jabado, MD, PhD
- Tony Kouzarides, PhD, FMedSci, FRS
University of Cambridge
- Anna Mapp, PhD
University of Michigan
- Kevan Shokat, PhD
University of California, San Francisco
We invite abstract submissions for the upcoming Bringing Chemistry to Medicine Symposium. The symposium focuses on the interface of chemical and biomedical sciences. We welcome abstracts from researchers in all areas of drug discovery, chemical biology, medicinal chemistry, transcription therapy, and related fields.
You must register for the symposium as an in-person attendee to submit an abstract.
Selected abstracts will be invited for oral or poster presentations. A limited number of travel awards will be available for students and trainees submitting abstracts. We encourage abstract submissions from trainees, postdocs, and established investigators.
Instructions for Abstract Submission
Submission deadline is July 14, 2023 by 11:59 PM CST.
For questions regarding abstract submission, please contact the Bringing Chemistry to Medicine program committee at BC2M@stjude.org.
- Authors may submit any number of abstracts.
- Abstracts must be written in English.
- Abstracts are limited to 2900 characters including spaces.
- Use a concise title.
- List affiliations of author(s) as briefly as possible with name, degree, hospital, city, state, country.
- Use standard and well-accepted abbreviations.
- One table or graphic may be inserted in a .jpg format only.
- Abstract content should be single spaced, typed in sentence case and contain:
Watch our Archived Lectures
In 2020, 2021 and 2022, St. Jude hosted exciting two-day events focused on Transcription Therapy and Chemical Biology and Therapeutics.
Transcription Therapy at St. Jude
Over decades of research, scientists in the St. Jude Comprehensive Cancer Center and others have discovered that several pediatric cancers emerge due to disruption in chromatin and epigenetic states and dysfunctional transcriptional regulation. While gene regulation in general has long been considered “undruggable,” scientists in the St. Jude Department of Chemical Biology & Therapeutics (CBT) have created synthetic gene regulators and are devising new chemical approaches to inhibit or degrade malfunctioning components of chromatin and gene regulatory machineries. This work builds on the history of St. Jude as a pioneer in the therapeutic use of small molecules targeting gene regulation, most notably the application of glucocorticoid receptor agonists into chemotherapy regimens for pediatric patients with acute lymphoblastic lymphoma (ALL). The drugging of this transcription factor helped to dramatically increase overall survival rates for newly diagnosed ALL to 94% at St. Jude.
Learn more about transcription therapy at St. Jude Learn more